Skip to main content
Fig. 4 | Thrombosis Journal

Fig. 4

From: An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention

Fig. 4

1-year Adverse Events in Groups of Different Level of PLADP. Patients were stratified into groups of NOPR (25.5–37.4%), HOPR (≥37.5%) and LOPR (< 25.5%). ** represents P < 0.001 for bleeding events compared with the NOPR group. †† represents P < 0.001 for net adverse clinical events compared with the NOPR group. PLADP, ADP induced platelet aggregation; NOPR, normal on-treatment platelet reactivity; HOPR, high on-treatment platelet reactivity; LOPR, low on-treatment platelet reactivity

Back to article page